Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Fig. 1

Mode of action of a triomab antibody. The trifunctional antibody unites tumor cell, T cell and accessory cells to form a tri-cell complex to induce tumor cell destruction and phagocytosis. Abbreviations: ADCC, antibody dependent cellular cytotoxicity; DC, dendritic cell; DC-CK1, dendritic cell cytokine 1; IL, interleukin; LFA, leukocyte function associated antigen; NK, natural killer cell; TNF-α, tumor necrosis factor alpha; INF-γ, interferon gamma; GM-CSF, granulocyte macrophage colony-stimulating factor. Modified10,12

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us